LA Emens

Abstract GS1-04: IMpassion130: Efficacy in immune biomarker subgroups from the global, randomized, double-blind, placebo-controlled, phase III study of atezolizumab + <i>nab</i>-paclitaxel in patients with treatment-naïve, locally advanced or metastatic triple-negative breast cancer

LA Emens, Sherene Loi, HS Rugo et al. · Cancer Research · 2019 · 81 citations

Breast Oncology, A-nabpx Efficacy, Immunology +16

Abstract PD3-01: Results from KATE2, a randomized phase 2 study of atezolizumab (atezo)+trastuzumab emtansine (T-DM1) vs placebo (pbo)+T-DM1 in previously treated HER2+ advanced breast cancer (BC)

LA Emens, Francisco J. Esteva, M Beresford et al. · Cancer Research · 2019 · 47 citations

Breast Oncology, Immunology, Immunoediting +20

329TiP KATE3: A phase III study of trastuzumab emtansine (T-DM1) in combination with atezolizumab or placebo in patients with previously treated HER2-positive and PD-L1–positive locally advanced or metastatic breast cancer

Sherene Loi, Eun‐Kee Song, Mark Harries et al. · Annals of Oncology · 2021 · 17 citations

Metastatic Breast Cancer, Oncology, Breast Oncology +10

Abstract OT2-06-04: MORPHEUS: A phase Ib/II trial platform evaluating the safety and efficacy of multiple cancer immunotherapy combinations in patients with hormone receptor–positive and triple-negative breast cancer

DA Yardley, Maysa Abu‐Khalaf, Valentina Boni et al. · Cancer Research · 2019 · 11 citations